Methods Inf Med 1977; 16(04): 240-247
DOI: 10.1055/s-0038-1636602
DRUG MONITORING
Schattauer GmbH

One Method for the Systematic Evaluation of Adverse Drug Experience Data within a Pharmaceutical Firm

EINE VON EINER PHARMAZEUTISCHEN FIRMA ANGEWANDTE METHODE ZUE, SYSTEMATISCHEN BEWERTUNG DER ERFAHRUNGSDATEN VON ARZNEIMITTEL-NEBENWIRKUNGEN
W. F. Westlin
1   From the Medical Services Department, Sandoz Pharmaceuticals, East Hanover, New Jersey)
,
R. V. Cuddihy
1   From the Medical Services Department, Sandoz Pharmaceuticals, East Hanover, New Jersey)
,
R. J. BursiK
1   From the Medical Services Department, Sandoz Pharmaceuticals, East Hanover, New Jersey)
,
Beverley G. Seifert
1   From the Medical Services Department, Sandoz Pharmaceuticals, East Hanover, New Jersey)
,
Joyce G. Koelle
1   From the Medical Services Department, Sandoz Pharmaceuticals, East Hanover, New Jersey)
› Author Affiliations
Further Information

Publication History

Publication Date:
16 February 2018 (online)

Post-marketing surveillance of drug adverse experience incidents constitutes a major interest for physicians, pharmaceutical firms and federal regulatory bodies alike. The development and operation of a total information system for the management of adverse experience data related to a single pharmaceutical firm’s commercial products is described. Data is carefully collected from clinical investigations, visits and correspondence with practicing physicians and from the published medical literature. Each such alleged incident is carefully medically reviewed. Thereafter, the data is reported to the United States Food and Drug Administration (FDA) and entered into an internal data bank. Computer management of the data for information retrieval and trend analysis was accomplished in a rapid and economical fashion by the use of commercially available computer programming packages. This approach, combining meticulous data collection, computer management of files and links to the firm’s FDA reporting system offers a flexible, thorough approach operative within the economic constraints naturally inherent within a single corporation.

Die Überwachung des Auftretens von Nebenwirkungen nach Einführung eines Arzneimittels ist in gleicher Weise für Ärzte, pharmazeutische Firmen und staatliche Kontrollstellen von größtem Interesse. Es werden Entwicklung und Anwendung eines umfassenden Informationssystems zur Handhabung von Erfahrungsdaten über Nebenwirkungen der Handelspräparate einer einzelnen pharmazeutischen Firma beschrieben. Die Daten werden sorgfältig aus klinischen Prüfungen, Besuchen und Schriftverkehr mit praktizierenden Ärzten sowie medizinischen Publikationen zusammengestellt. Jeder angebliche Vorfall wird sorgfältig medizinisch überprüft. Anschließend werden die Daten der amerikanischen Food and Drug Administration (FDA) gemeldet mul in einer internen Datenbank gespeichert. Die Verwendmag kommerziell erhältlicher Computerprogramme ermöglichte eine rasche und wirtschaftliche Computerbearbeitung der Daten zur Informationsrecherehe und Trendanalyse. Die Kombination von genauester Datenerfassung, Computerbearbeitung der Datensammlung und Verbindung zum firmeneigenen FDA-Meldesystem bietet eine bewegliche, umfassende Methode, die innerhalb der in einer Einzelfirma vorhandenen wirtschaftlichen Grenzen anwendbar ist.

 
  • References

  • 1 Buchanan O. H. The Computer Processing of Clinical Data for a New Drug Application. A Bibliography, presented at the Third Annual Meeting, Drug Information Association. Philadelphia, Pennsylvania: May 24—26, 1967
  • 2 Cuddihy R. V, Ring W. S, Augustine N. F. Modification of a Management Information System Software Package to Process Drug Reaction Data. Meth. Inform. Med 10 1971; 9-18.
  • 3 Deiohmann W. B. Progress Report: AMA Registry on Adverse Reactions due to Occupational Exposures. J. occup. Med 13 1971; 577-580.
  • 4 De Nosaquo N. The Registry on Adverse Reactions of the American Medical Association. Meth. Inform. Med 04 1965; 15-21.
  • 5 De Nosaquo N. A.M.A. Registry on Adverse Reactions. J. chem. Doc 09 1969; 59-65.
  • 6 Esch A. F. Food and Drug Administration Drug Experience Reporting System. J. chem. Doc 09 1969; 66-70.
  • 7 Finney D. J. Systematic Signalling of Adverse Reactions to Drugs. Meth. Inform. Med 13 1974; 1-10.
  • 8 Holden J. M.C, Itil T. M. The Application of Automated Techniques in Assessing Psychotropic-Drug-Induced Side Effects. Amer. J. Psychiat 125 1968; 562-569.
  • 9 Information Science Inc.: General Retrieval System. Programmer’s Reference Manual (360-D. D. S.).. Version 7, Revised: Dec. 2, 1968
  • 10 Jick H. History of Prospective Epidemiology Drug Studies. Drug Inform. Bull 02 1968; 94-96.
  • 11 Karpinski R. Personal Communication.
  • 12 Long J. W. FDA’s Adverse Drug Reaction Information System. Drug Reaction Information System. Drug Inform. Bull 01 1967; 114-119.
  • 13 Meleney H. E, Fraser M. L. A Retrospective Study of Drug Usage and Adverse Drug Reactions in Hospital Outpatients. Drug Inform. Bull 02 1968; 96-101.
  • 14 Napke E, Bishop J. The Canadian Drug Adverse Reaction Reporting Program. Canadian med. Ass. J 95 1966; 1307-1309.
  • 15 Program Products Inc.: The Data Analyzer. Technical Reference Manual. 1973
  • 16 Sadusk Jr J. F. The Monitoring of Adverse Reactions to Drugs. Drug Inform. Bull 02 1969; 66-72.
  • 17 Smith J. W. A Hospital Adverse Reaction Reporting Program. Hospitals 40 1966; 90-96.
  • 18 Teal T. W. An Adverse Experience Processing Procedure. Presented at DIA Computer Workshop II. Cleveland, Ohio: March 27-29 1968
  • 19 Venn R. D. Experience with the Collection and Evaluation of Drug Adverse Reaction Data.. Proc. Tenth Meeting of the European Society for the Study of Drug Toxicity, Oxford/ England, April, 1968. Excerpta Medica Internat. Cong. Ser 181 1968; 152-157.
  • 20 Wade O. L, Beeley L. Monitoring Adverse Reaction to Drugs: Toward a Therapeutic Audit. Internat. J. Health Serv 04 1974; 109-123.